Quantum BioPharma Ltd. (NASDAQ: QNTM) is advancing Lucid-MS toward a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis after the U.S. Food and Drug Administration cleared its Investigational New Drug application. The milestone matters because Lucid-MS is a patented, first-in-class non-covalent inhibitor of peptidyl arginine deiminase 2, or PAD2, that is designed to target demyelination directly rather than suppress the immune system. If successful, that mechanism could offer a different approach for a disease in which current therapies largely focus on immune modulation and often leave patients with unmet needs related to myelin repair.
The FDA clearance is not a guarantee of approval, but it allows the company to proceed with clinical testing in humans under a defined regulatory framework. For Quantum BioPharma, the IND green light represents a transition from preclinical work into a more expensive and data-driven phase of development, where safety and early efficacy signals will be closely watched by investors and clinicians. The trial's randomized, double-blind, placebo-controlled design is considered the gold standard for determining whether a treatment provides meaningful benefit beyond a placebo effect.
Quantum BioPharma is also collaborating with Massachusetts General Hospital and Harvard Medical School on research involving the [¹⁸F]3F4AP PET imaging tracer. That tracer is being evaluated as a way to visualize and measure demyelination, which could improve how researchers select patients, track disease progression, and assess whether a therapy is actually repairing myelin. The imaging work is significant because multiple sclerosis trials have historically lacked precise biomarkers for demyelination, making it harder to demonstrate a direct treatment effect on the underlying pathology.
The company's broader pipeline includes UNBUZZD, an alcohol misuse product that was spun out to Unbuzzd Wellness Inc., with Quantum retaining a 19.84% ownership stake as of March 31, 2026, and royalty payments of 7% of sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. That structure gives the company potential non-dilutive revenue while it focuses on its central nervous system assets.
The announcement also places Quantum BioPharma in a broader biopharma context alongside companies advancing therapies in areas of unmet medical need. Novartis AG (NYSE: NVS) received FDA approval for Pluvicto in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. (NYSE: MRK) had its supplemental Biologics License Application for ENFLONSIA accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. (NASDAQ: TGTX) initiated a phase 2 trial of BRIUMVI in adults with treatment-resistant schizophrenia. Bristol-Myers Squibb Company (NYSE: BMY) reported positive phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma.
For Quantum BioPharma, the key implication is that Lucid-MS now has a regulatory path into phase 2 testing, which could generate the clinical evidence needed to attract partners or additional financing. The outcome of that trial will determine whether the PAD2 inhibition approach can be validated in humans and whether the company can differentiate itself in a competitive multiple sclerosis landscape. To view the full press release, visit https://ibn.fm/lCey9. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
